Samsung Biologics Capabilities Update June 2026: ADC

Samsung Biologics is expanding its bioconjugation capabilities beyond traditional antibody–drug conjugates (ADCs) to support a broader range of next-generation modalities, including emerging non-cytotoxic formats such as antibody–oligonucleotide conjugates (AOCs) and antibody–siRNA conjugates (ARCs). This evolution is powered by the co-location of our GMP-grade manufacturing facilities and dedicated ADC infrastructure, enabling a highly integrated and streamlined development and production workflow.

In this video, we will provide a capacity and capability update highlighting our end-to-end bioconjugation services — from early development through commercial manufacturing. Viewers will gain insight into how our scalable, flexible platform is designed to support increasingly complex therapeutic modalities and accelerate the path from concept to clinic and beyond.